• Menachem M Weiner, Hung-Mo Lin, Dennis Danforth, Srikar Rao, Leila Hosseinian, and Gregory W Fischer.
• Department of Anesthesiology, Icahn School of Medicine at Mount Sinai, New York, NY. Electronic address: menachem.weiner@mountsinai.org.
• J. Cardiothorac. Vasc. Anesth.. 2013 Dec 1;27(6):1233-8.

ObjectivesThe purpose of this study was to investigate whether patients who received methylene blue as treatment for vasoplegia during cardiac surgery with cardiopulmonary bypass had decreased morbidity and mortality.DesignRetrospective analysis.SettingSingle tertiary care university hospital.ParticipantsAdult patients who suffered from vasoplegia and underwent all types of cardiac surgery with cardiopulmonary bypass at this institution between 2007 and 2008.InterventionsWith IRB approval, the authors reviewed the charts of the identified patients and divided them into 2 groups based on whether they had received methylene blue. Two hundred twenty-six patients were identified who met the inclusion criteria for the study. Fifty-seven of these patients had received methylene blue for vasoplegia. The authors collected data on preoperative and intraoperative variables as well as outcomes.Measurements And Main ResultsThe patients who received methylene blue had higher rates of in-hospital mortality, a compilation of morbidities, as well as renal failure and hyperbilirubinemia. A multiple logistic regression model demonstrated that receiving methylene blue was an independent predictor of in-hospital mortality (p value: 0.007, OR 4.26, 95% CI: 1.49-12.12), compilation of morbidities (p value: 0.001, OR 4.80, 95% CI: 1.85-12.43), and hyperbilirubinemia (p value:<0.001, OR 6.58, 95% CI: 2.91-14.89). Using propensity score matching, the association with morbidity was again seen but the association with mortality was not found.ConclusionsThe current study identified the use of methylene blue as treatment for vasoplegia to be independently associated with poor outcomes. While further studies are required, a thorough risk-benefit analysis should be applied before using methylene blue and, perhaps, it should be relegated to rescue use and not as first-line therapy.Copyright © 2013 Elsevier Inc. All rights reserved.

31 keywords...

hide…